Market capitalization | $48.73m |
Enterprise Value | $49.14m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.84 |
P/S ratio (TTM) P/S ratio | 5.79 |
P/B ratio (TTM) P/B ratio | 9.67 |
Revenue growth (TTM) Revenue growth | -56.70% |
Revenue (TTM) Revenue | $8.41m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a DURECT Corporation forecast:
2 Analysts have issued a DURECT Corporation forecast:
Jun '24 |
+/-
%
|
||
Revenue | 8.41 8.41 |
57%
57%
|
|
Gross Profit | 6.92 6.92 |
61%
61%
|
|
EBITDA | -25 -25 |
28%
28%
|
EBIT (Operating Income) EBIT | -25 -25 |
28%
28%
|
Net Profit | -16 -16 |
56%
56%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
DURECT Corp. is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
Head office | United States |
CEO | James Brown |
Employees | 58 |
Founded | 1998 |
Website | www.durect.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.